GlassScriptPhysician profile
Kari L Edling
NPI 1295987089
$22,972.49
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $6,316 · 2021: $44.21 · 2022: $22.98 · 2023: $50.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11,187.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,159.42 | 2019-2020 | |
| Novo Nordisk INC | $1,636.67 | 2019-2023 | Wegovy |
| Amgen INC. | $245.68 | 2019-2020 | |
| Corcept Therapeutics | $216.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.39 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $193.58 | 2019-2021 | |
| Insulet Corporation | $139.69 | 2019-2020 | |
| Mannkind Corporation | $108.86 | 2019 | |
| Abbott Laboratories | $101.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $97.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $79.05 | 2019 | |
| Abbvie INC. | $73.57 | 2019 | |
| Amneal Pharmaceuticals LLC | $64.26 | 2019 | |
| Pfizer INC. | $61.83 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $54.24 | 2019 | |
| Vivus LLC | $41.90 | 2019-2020 | |
| Radius Health, INC. | $34.87 | 2019 | |
| Ibsa Pharma INC. | $33.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.32 | 2020 | |
| Companion Medical, INC. | $33.19 | 2019-2020 | |
| Shire North American Group INC | $32.86 | 2019 | |
| Endo Pharmaceuticals INC. | $22.15 | 2019 | |
| Horizon Therapeutics Plc | $20.64 | 2019 | |
| Lifescan, INC. | $20.50 | 2019 | |
| Antares Pharma, INC. | $18.95 | 2020 | |
| Esperion Therapeutics, INC. | $15.53 | 2020 | |
| Dexcom, INC. | $14.48 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.88 | 2019 | |
| Valeritas, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Edling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.